Anti-inflammatory cytokine profile in acute coronary syndromes: behavior of interleukin-10 in association with serum metalloproteinases and proinflammatory cytokines.

[1]  A. Kastrati,et al.  Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. , 2001, Atherosclerosis.

[2]  A. Tedgui,et al.  Expression of Interleukin-18 in Human Atherosclerotic Plaques and Relation to Plaque Instability , 2001, Circulation.

[3]  J. Kaski,et al.  Serum Levels of the Antiinflammatory Cytokine Interleukin-10 Are Decreased in Patients With Unstable Angina , 2001, Circulation.

[4]  T. Kanda,et al.  Correlation of circulating interleukin-10 with thyroid hormone in acute myocardial infarction. , 2001, Research communications in molecular pathology and pharmacology.

[5]  J. E. Park,et al.  Tumor necrosis factor receptor superfamily 12 may destabilize atherosclerotic plaques by inducing matrix metalloproteinases. , 2001, Japanese circulation journal.

[6]  H. Granger,et al.  Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10. , 2000, Blood.

[7]  D. Scherman,et al.  Antiangiogenic Effect of Interleukin-10 in Ischemia-Induced Angiogenesis in Mice Hindlimb , 2000, Circulation research.

[8]  Z. Yang,et al.  Crucial role of endogenous interleukin-10 production in myocardial ischemia/reperfusion injury. , 2000, Circulation.

[9]  M. Territo,et al.  Interleukin-10 blocks atherosclerotic events in vitro and in vivo. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[10]  R. Terkeltaub.  IL-10: An "immunologic scalpel" for atherosclerosis? , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[11]  M. Bureau,et al.  Protective role of interleukin-10 in atherosclerosis. , 1999, Circulation research.

[12]  G. Specchia,et al.  Plasma levels of interleukin 2, 6, 10 and phenotypic characterization of circulating T lymphocytes in ischemic heart disease. , 1999, Atherosclerosis.

[13]  T. Yamashita,et al.  Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome. , 1999, Critical care medicine.

[14]  L. Petit,et al.  Interleukin-8 mediates downregulation of tissue inhibitor of metalloproteinase-1 expression in cholesterol-loaded human macrophages: relevance to stability of atherosclerotic plaque. , 1999, Circulation.

[15]  P. Durrington.  Triglycerides are more important in atherosclerosis than epidemiology has suggested. , 1998, Atherosclerosis.

[16]  K. Koch,et al.  Mast cell infiltration in acute coronary syndromes: implications for plaque rupture. , 1998, Journal of the American College of Cardiology.

[17]  T. Ueno,et al.  Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. , 1998, Journal of the American College of Cardiology.

[18]  M. Davies.  Reactive oxygen species, metalloproteinases, and plaque stability. , 1998, Circulation.

[19]  P. Ridker,et al.  Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. , 1998, Circulation.

[20]  A. Lentsch,et al.  In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. , 1997, The Journal of clinical investigation.

[21]  M. Feldmann,et al.  Interleukin‐10 rescues T cells from apoptotic cell death: association with an upregulation of Bcl‐2 , 1997, Immunology.

[22]  A. Maseri.  Inflammation, atherosclerosis, and ischemic events -- exploring the hidden side of the moon. , 1997, The New England journal of medicine.

[23]  N. Arakawa,et al.  Elevated plasma levels of interleukin-1 receptor antagonist and interleukin-10 in patients with acute myocardial infarction. , 1997, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[24]  G. D. De Meyer,et al.  Luminal foam cell accumulation is associated with smooth muscle cell death in the intimal thickening of human saphenous vein grafts. , 1996, Circulation.

[25]  D. Strachan,et al.  C Reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study , 1996, BMJ.

[26]  A. Serraf,et al.  Interleukin-10 release related to cardiopulmonary bypass in infants undergoing cardiac operations. , 1996, The Journal of thoracic and cardiovascular surgery.

[27]  J. Bultinck,et al.  Distribution of cell replication and apoptosis in atherosclerotic plaques of cholesterol-fed rabbits. , 1996, Atherosclerosis.

[28]  J. Dayer,et al.  IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. , 1995, The Journal of clinical investigation.

[29]  V. Fuster,et al.  Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. , 1995, Circulation.

[30]  Y. Nimura,et al.  Endogenous interleukin 10 prevents apoptosis in macrophages during Salmonella infection. , 1995, Biochemical and biophysical research communications.

[31]  V. Fuster,et al.  Coronary plaque disruption. , 1995, Circulation.

[32]  Peng Wang,et al.  Interleukin (IL)-10 Inhibits Nuclear Factor B (NFB) Activation in Human Monocytes , 1995, The Journal of Biological Chemistry.

[33]  J. Isner,et al.  Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. , 1995, Circulation.

[34]  Y. Okada,et al.  A one-step sandwich enzyme immunoassay for inactive precursor and complexed forms of human matrix metalloproteinase 9 (92 kDa gelatinase/type IV collagenase, gelatinase B) using monoclonal antibodies. , 1994, Clinica chimica acta; international journal of clinical chemistry.

[35]  V. Fuster,et al.  Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. , 1994, Circulation.

[36]  W. Stetler-Stevenson,et al.  Interleukin 10 suppression of monocyte prostaglandin H synthase-2. Mechanism of inhibition of prostaglandin-dependent matrix metalloproteinase production. , 1994, The Journal of biological chemistry.

[37]  Y. Okada,et al.  A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies. , 1993, Clinica chimica acta; international journal of clinical chemistry.

[38]  R. Ross.  The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[39]  U. Ikeda,et al.  Serum interleukin 6 levels become elevated in acute myocardial infarction. , 1992, Journal of molecular and cellular cardiology.

[40]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (2). , 1992, The New England journal of medicine.

[41]  E. Falk,et al.  Coronary thrombosis: pathogenesis and clinical manifestations. , 1991, The American journal of cardiology.

[42]  P. Shah.  Pathophysiology of unstable angina. , 1991, Cardiology clinics.

[43]  W. Harland,et al.  Sudden coronary death in Glasgow: nature and frequency of acute coronary lesions. , 1987, British heart journal.

[44]  M. Entman,et al.  The inflammatory response in myocardial infarction. , 2002, Cardiovascular research.